M. J. Allington

Learn More
IMMUNOLOGICAL responses appear to be involved in limiting the extent of some human tumours, and stimulation of this immune response is currently being investi-(fated as a treatment for cancer, both as adjuvant therapy following radical surgery and in advanced disease. Levamisole, Bacille Calmette-Guerin and Coryne-bacterium parvum are all known to stimulate(More)
Fibrinolytic and other factors have been measured in 73 patients with systemic lupus erythematosus or related conditions to determine whether clinical thrombosis, a common feature of these disorders, is associated with defective fibrinolysis. Twenty five of 72 (35%) patients, compared with two of 22 (9%) controls, showed a low level of plasminogen activator(More)
Elevated plasma beta thromboglobulin (betatg) and decreased intracellular platelet betatg were found in patients with various myeloproliferative disorders. In secondary thrombocytosis, similar, but less marked changes were found. The abnormalities were increased during episodes of clinical thrombosis and could be suppressed in two-thirds of cases by aspirin(More)
The risk of developing an overt malignancy after an isolated deep venous thrombosis (DVT) is poorly documented. We therefore reviewed a series of patients in whom a solitary idiopathic DVT had been proven by venography at least 12 months earlier. No patient had developed a malignancy at follow-up. However, decreased fibrinolytic activity was observed in(More)
Anticoagulant therapy is a well-established treatment for coronary thrombosis, pulmonary embolus, and other thrombotic or embolic episodes. The anticoagulant drugs used are usually those of the dicoumarol group. It is known that this group of drugs, " dindevan," "tromexan," "marcoumar," etc., depress the production of prothrombin and possibly to a greater(More)
An in vitro model is described which utilizes human umbilical vein endothelial cells cultured on plastic microcarrier spheres and perfused with serum-free medium. This model was used to study the acute release of von Willebrand factor following stimulation of the cells with putative agonists. Thrombin, plasmin and interleukin-1 were found to release von(More)